These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 32198139)

  • 21. Loss of 4.1N in epithelial ovarian cancer results in EMT and matrix-detached cell death resistance.
    Wang D; Zhang L; Hu A; Wang Y; Liu Y; Yang J; Du N; An X; Wu C; Liu C
    Protein Cell; 2021 Feb; 12(2):107-127. PubMed ID: 32448967
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting estrogen metabolism in high-grade serous ovarian cancer shows promise to overcome platinum resistance.
    Marolt N; Pavlič R; Kreft T; Gjogorska M; Rižner TL
    Biomed Pharmacother; 2024 Aug; 177():117069. PubMed ID: 38968802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NQO1/CPT1A promotes the progression of pancreatic adenocarcinoma via fatty acid oxidation.
    Xu R; Liu Y; Ma L; Sun Y; Liu H; Yang Y; Jin T; Yang D
    Acta Biochim Biophys Sin (Shanghai); 2023 May; 55(5):758-768. PubMed ID: 37249337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
    Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
    Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
    [TBL] [Abstract][Full Text] [Related]  

  • 25. iRGD-modified exosomes effectively deliver CPT1A siRNA to colon cancer cells, reversing oxaliplatin resistance by regulating fatty acid oxidation.
    Lin D; Zhang H; Liu R; Deng T; Ning T; Bai M; Yang Y; Zhu K; Wang J; Duan J; Ge S; Sun B; Ying G; Ba Y
    Mol Oncol; 2021 Dec; 15(12):3430-3446. PubMed ID: 34213835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment.
    Moskovich D; Finkelshtein Y; Alfandari A; Rosemarin A; Lifschytz T; Weisz A; Mondal S; Ungati H; Katzav A; Kidron D; Mugesh G; Ellis M; Lerer B; Ashur-Fabian O
    Oncogene; 2021 Nov; 40(44):6248-6257. PubMed ID: 34556811
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient-derived cell line models revealed therapeutic targets and molecular mechanisms underlying disease progression of high grade serous ovarian cancer.
    Kreuzinger C; von der Decken I; Wolf A; Gamperl M; Koller J; Karacs J; Pfaffinger S; Bartl T; Reinthaller A; Grimm C; Singer CF; Braicu EI; Cunnea P; Gourley C; Smeets D; Boeckx B; Lambrechts D; Perco P; Horvat R; Berns EMJJ; Cacsire Castillo-Tong D
    Cancer Lett; 2019 Sep; 459():1-12. PubMed ID: 31150822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.
    Barger CJ; Zhang W; Hillman J; Stablewski AB; Higgins MJ; Vanderhyden BC; Odunsi K; Karpf AR
    Oncotarget; 2015 Sep; 6(29):27613-27. PubMed ID: 26243836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anticancer effects of Erzhimaoling decoction in high-grade serous ovarian cancer in vitro and in vivo.
    Yang L; Liu J; Zhang J; Shao F; Jin Y; Xing J; Zhou H; Yu A
    Eur J Med Res; 2024 Aug; 29(1):405. PubMed ID: 39103890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extracellular matrix in high-grade serous ovarian cancer: Advances in understanding of carcinogenesis and cancer biology.
    Brown Y; Hua S; Tanwar PS
    Matrix Biol; 2023 Apr; 118():16-46. PubMed ID: 36781087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Upregulation of the Long Noncoding RNA CASC10 Promotes Cisplatin Resistance in High-Grade Serous Ovarian Cancer.
    Noriega-Rivera R; Rivera-Serrano M; Rabelo-Fernandez RJ; Pérez-Santiago J; Valiyeva F; Vivas-Mejía PE
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887085
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma.
    Morra F; Merolla F; Damia G; Ricci F; Varricchio S; Ilardi G; Arenare L; Califano D; Napolitano V; Fruscio R; Melillo RM; Palazzo L; Celetti A
    J Exp Clin Cancer Res; 2022 Aug; 41(1):245. PubMed ID: 35964058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined MEK and BCL-2/X
    Iavarone C; Zervantonakis IK; Selfors LM; Palakurthi S; Liu JF; Drapkin R; Matulonis UA; Hallberg D; Velculescu VE; Leverson JD; Sampath D; Mills GB; Brugge JS
    Mol Cancer Ther; 2019 Mar; 18(3):642-655. PubMed ID: 30679390
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LGR4 maintains HGSOC cell epithelial phenotype and stem-like traits.
    Wang Z; Yin P; Sun Y; Na L; Gao J; Wang W; Zhao C
    Gynecol Oncol; 2020 Dec; 159(3):839-849. PubMed ID: 32980127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Carnitine palmitoyltransferase 1A prevents fatty acid-induced adipocyte dysfunction through suppression of c-Jun N-terminal kinase.
    Gao X; Li K; Hui X; Kong X; Sweeney G; Wang Y; Xu A; Teng M; Liu P; Wu D
    Biochem J; 2011 May; 435(3):723-32. PubMed ID: 21348853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rescue of p53 functions by in vitro-transcribed mRNA impedes the growth of high-grade serous ovarian cancer.
    Raab M; Kostova I; Peña-Llopis S; Fietz D; Kressin M; Aberoumandi SM; Ullrich E; Becker S; Sanhaji M; Strebhardt K
    Cancer Commun (Lond); 2024 Jan; 44(1):101-126. PubMed ID: 38140698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FANCD2 expression affects platinum response and further characteristics of high grade serous ovarian cancer in cells with different genetic backgrounds.
    Taylor SJ; Hollis RL; Gourley C; Herrington CS; Langdon SP; Arends MJ
    Exp Mol Pathol; 2024 Aug; 138():104916. PubMed ID: 38959632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PGC1α/CEBPB/CPT1A axis promotes radiation resistance of nasopharyngeal carcinoma through activating fatty acid oxidation.
    Du Q; Tan Z; Shi F; Tang M; Xie L; Zhao L; Li Y; Hu J; Zhou M; Bode A; Luo X; Cao Y
    Cancer Sci; 2019 Jun; 110(6):2050-2062. PubMed ID: 30945396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition.
    Parmar K; Kochupurakkal BS; Lazaro JB; Wang ZC; Palakurthi S; Kirschmeier PT; Yang C; Sambel LA; Färkkilä A; Reznichenko E; Reavis HD; Dunn CE; Zou L; Do KT; Konstantinopoulos PA; Matulonis UA; Liu JF; D'Andrea AD; Shapiro GI
    Clin Cancer Res; 2019 Oct; 25(20):6127-6140. PubMed ID: 31409614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ATF3 characterizes aggressive drug-tolerant persister cells in HGSOC.
    Böpple K; Oren Y; Henry WS; Dong M; Weller S; Thiel J; Kleih M; Gaißler A; Zipperer D; Kopp HG; Aylon Y; Oren M; Essmann F; Liang C; Aulitzky WE
    Cell Death Dis; 2024 Apr; 15(4):290. PubMed ID: 38658567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.